COST picto_medicine
BMBS
Members Area
 
Homepage
Domains and Actions
>BMBS
>Actions
>Meetings
>in Detail
>DC Members
>DC Rapporteurs
>DC BMBS Liaisons
Search Actions
GO TOP GO BOTTOM
CE EU
COST is supported by the EU RTD Framework Programme
 
GO BOTTOM GO BOTTOM
GO TOP GO BOTTOM
ESF
ESF provides the COST Office through a European Commission contract
 
GO BOTTOM GO BOTTOM
GO TOP GO BOTTOM
CE EU
The Council of the European Union provides the COST Secretariat
 
GO BOTTOM GO BOTTOM

Action BM0603: Inflammation in Brain Disease (NEURINFNET)


 
Action overview

Printable version

The Main Objective of the Action is to gain new understanding of neuroinflammatory and neurodegenerative processes as they occur in multiple sclerosis and Alzheimer's disease, so as to facilitate development of improved therapies by drawing together knowledge from study of individual diseases. The Operational Goal of this Action is to create a network of basic scientists and clinical researchers with expertise in inflammation and degenerative disease of the brain, in order to: 1. Integrate studies, approaches and techniques for study of neuroinflammation and neurodegeneration, 2. Train young researchers by cross-cutting exposure to all aspects of these two major diseases, and, 3. Provide scientific insight that guides clinical research and practice. Targeted goals within this operational framework To improve and integrate understanding of these diseases with specific reference to: - Gene expression/repression in disease - Blood-brain interactions - Cellular dynamics of inflammation in the CNS - Demyelinating pathology - Degenerative pathology - Inflammation-associated neurodegeneration and regeneration - Glial responses and signalling - Immune regulation - Neuro- and glio-genesis and cell replacement The components listed are crucial to success, as well as realistic in view of the expertise in participating laboratories and groups to be recruited. These components are combined to address key questions that guide development of therapies for MS and AD as well as other major neurological diseases in adults.



Domain : Biomedicine and Molecular Biosciences
Action title : Inflammation in Brain Disease (NEURINFNET)



Action details Parties
  Country Date Status
MoU : 303/06
CSO Approval date : 20/11/2006
Entry into force : 18/04/2007
End of Action : 04/06/2011
Austria 17/04/2007 Confirmed
Denmark 22/05/2007 Confirmed
France 27/06/2008 Confirmed
Germany 18/04/2007 Confirmed
Greece 20/04/2007 Confirmed
Ireland 04/06/2009 Confirmed
Israel 12/09/2007 Confirmed
Italy 20/04/2007 Confirmed
Netherlands 20/04/2007 Confirmed
Norway 12/06/2007 Confirmed
Poland 17/04/2007 Confirmed
Portugal 10/10/2007 Confirmed
Serbia 08/02/2010 Confirmed
Spain 17/04/2007 Confirmed
Sweden 01/10/2008 Confirmed
Switzerland 20/04/2007 Confirmed
United Kingdom 17/04/2007 Confirmed
Total 17  
 
Non COST Institutions
Institution NameCountry
Bogomoletz Institute of Physiology Ukraine
Ilia Chavchavadze State University Georgia
 
Intentions to accept the MoU
Country   Status
Total 0  


Action Web Site: http://www1.sdu.dk/multi/neurinfnet

Notice board

More Information can be obtained through the website :
http://www1.sdu.dk/multi/neurinfnet

or  by contacting the Chair of the Action :
Prof. Trevor OWENS

Rapporteur :
Prof. Roland POCHET

Science Officer :
Dr Magdalena RADWANSKA

Administrative Officer :
Ms Jeannette NCHUNG



Legal Notice | Accessibility | Sitemap top